Tilray Brands (TLRY) Total Non-Current Liabilities (2019 - 2026)
Tilray Brands (TLRY) posted Total Non-Current Liabilities of $549.0 million for Q1 2026, little changed on a QoQ basis from $551.7 million in Q4 2025.
Tilray Brands (TLRY) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Tilray Brands' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $549.0 million for Q1 2026.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $549.0 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $549.0 million (changed N/A YoY) and the FY2025 annual result came in at $583.9 million, down 24.99% from the prior year.
- Total Non-Current Liabilities was $549.0 million for Q1 2026 at Tilray Brands, roughly flat from $551.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q1 2022 and bottomed at $549.0 million in Q1 2026.
- A 5-year average of $841.6 million and a median of $903.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slumped 35.52% — and 2023, when it fell 3.08%.
- Tilray Brands' Total Non-Current Liabilities stood at $991.0 million in 2022, then decreased by 5.43% to $937.2 million in 2023, then declined by 21.24% to $738.1 million in 2024, then retreated by 25.26% to $551.7 million in 2025, then decreased by 0.49% to $549.0 million in 2026.
- Business Quant data shows TLRY's Total Non-Current Liabilities at $549.0 million in Q1 2026, $551.7 million in Q4 2025, and $562.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | 548.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 548.95 Mn |
| Nov 30, 2025 | 551.67 Mn |
| Aug 31, 2025 | 561.99 Mn |
| May 31, 2025 | 583.90 Mn |
| Nov 30, 2024 | 738.13 Mn |
| Aug 31, 2024 | 778.35 Mn |
| May 31, 2024 | 778.40 Mn |
| Feb 29, 2024 | 869.61 Mn |
| Nov 30, 2023 | 937.20 Mn |
| Aug 31, 2023 | 987.69 Mn |
| May 31, 2023 | 977.10 Mn |
| Feb 28, 2023 | 965.79 Mn |
| Nov 30, 2022 | 991.05 Mn |
| Aug 31, 2022 | 1.03 Bn |
| May 31, 2022 | 1.01 Bn |
| Feb 28, 2022 | 1.16 Bn |
| Nov 30, 2021 | 1.29 Bn |
| Aug 31, 2021 | 1.60 Bn |
| May 31, 2021 | 1.56 Bn |
| Mar 31, 2020 | 719.84 Mn |